114 related articles for article (PubMed ID: 18927276)
1. Structural and functional basis for therapeutic modulation of p53 signaling.
Bassett EA; Wang W; Rastinejad F; El-Deiry WS
Clin Cancer Res; 2008 Oct; 14(20):6376-86. PubMed ID: 18927276
[TBL] [Abstract][Full Text] [Related]
2. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
3. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
Wiman KG
Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
[TBL] [Abstract][Full Text] [Related]
4. Prospects for p53-based cancer therapy.
Stokłosa T; Gołab J
Acta Biochim Pol; 2005; 52(2):321-8. PubMed ID: 15990917
[TBL] [Abstract][Full Text] [Related]
5. Targeting p53 for enhanced radio- and chemo-sensitivity.
Lu C; El-Deiry WS
Apoptosis; 2009 Apr; 14(4):597-606. PubMed ID: 19259822
[TBL] [Abstract][Full Text] [Related]
6. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
7. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
Resnick-Silverman L; Manfredi JJ
J Cell Biochem; 2006 Oct; 99(3):679-89. PubMed ID: 16676359
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
9. p53: prospects for cancer gene therapy.
Soddu S; Sacchi A
Cytokines Cell Mol Ther; 1998 Sep; 4(3):177-85. PubMed ID: 9825843
[TBL] [Abstract][Full Text] [Related]
10. [p53 as a molecular target for cancer therapy].
Ishioka C; Osada M; Gamo M; Kanamaru R
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
[TBL] [Abstract][Full Text] [Related]
11. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
12. p53-targeted cancer pharmacotherapy: move towards small molecule compounds.
Kim SH; Dass CR
J Pharm Pharmacol; 2011 May; 63(5):603-10. PubMed ID: 21492161
[TBL] [Abstract][Full Text] [Related]
13. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death.
Chari NS; Pinaire NL; Thorpe L; Medeiros LJ; Routbort MJ; McDonnell TJ
Apoptosis; 2009 Apr; 14(4):336-47. PubMed ID: 19229632
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
15. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
Kim E; Giese A; Deppert W
Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
[TBL] [Abstract][Full Text] [Related]
16. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
Bossi G; Sacchi A
Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
[TBL] [Abstract][Full Text] [Related]
17. Turning p53 on or off: either way may treat cancer.
Fisher DE
Drug Resist Updat; 2000 Apr; 3(2):77-79. PubMed ID: 11498370
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor.
Kuo PC; Tsao YP; Chang HW; Chen PH; Huang CW; Lin ST; Weng YT; Tsai TC; Shieh SY; Chen SL
Cancer Res; 2009 Dec; 69(23):8877-85. PubMed ID: 19903847
[TBL] [Abstract][Full Text] [Related]
19. In search of p53 target genes for the therapeutic manipulation of cancer.
Liu S; Seidel-Dugan C
Curr Opin Drug Discov Devel; 2006 Mar; 9(2):176-83. PubMed ID: 16566288
[TBL] [Abstract][Full Text] [Related]
20. Establishment of ponasterone A-inducible the wild-type p53 protein-expressing clones from HSC-1 cells, cell growth suppression by p53 expression and the suppression mechanism.
Hori M; Suzuki K; Udono MU; Yamauchi M; Mine M; Watanabe M; Kondo S; Hozumi Y
Arch Dermatol Res; 2009 Oct; 301(9):631-46. PubMed ID: 19009304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
